filmov
tv
A Novel Approach to Treat Parkinson’s Disease
![preview_player](https://i.ytimg.com/vi/XU35xG_KYFI/sddefault.jpg)
Показать описание
This video is based on a news article and its source material on a novel treatment for Parkinson’s Disease. We begin by covering the basis of what Parkinson’s Disease is and what its’ current treatment options are. We then discuss how current treatment options often result in adverse health effects. The toxins that cause Parkinson’s arise from excessive conversion of the amino acid tryptophan. As such, researchers at the pharmaceutical company NTRC in the Dutch city of Oss, in the Netherlands, have developed a substance called NTRC3531-0 that inhibits the production of these toxic by-products. By inhibiting the production of these toxic by-products, dopamine production is corrected, thereby reducing the symptoms that come with Parkinson’s disease. The results seem promising, and with more research, this treatment plan can be implemented for other diseases as well. This drug is not yet available for use, and researchers are continuing to assess its efficacy. Therefore, this video is meant to provide general information, and it does not act as a substitute for medical advice. Please consult your health care provider for more information.
This video was made by McMaster students Muntaha Ahmed, Stephanie Amoah, William Douglas, Youssef El-Sayes in collaboration with the McMaster Demystifying Medicine Program
Copyright McMaster University 2021.
References:
Perez-Pardo, P., Grobben, Y., Willemsen-Seegers, N., Hartog, M., Tutone, M., Muller, M., . . . Kraneveld, A. D. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. The Febs Journal. doi:10.1111/febs.15721
Saint-Cyr, J. A., Taylor, A. E., & Lang, A. E. (1993). Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology, 43(12, Suppl 6), S47–S52.
Keywords:
This video was made by McMaster students Muntaha Ahmed, Stephanie Amoah, William Douglas, Youssef El-Sayes in collaboration with the McMaster Demystifying Medicine Program
Copyright McMaster University 2021.
References:
Perez-Pardo, P., Grobben, Y., Willemsen-Seegers, N., Hartog, M., Tutone, M., Muller, M., . . . Kraneveld, A. D. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. The Febs Journal. doi:10.1111/febs.15721
Saint-Cyr, J. A., Taylor, A. E., & Lang, A. E. (1993). Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology, 43(12, Suppl 6), S47–S52.
Keywords:
Комментарии